



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Andrew A. YOUNG *et al.*

Group Art Unit: 1614

Appln. No.: 09/889,330

Examiner: To Be Assigned

371 Filing Date: December 27, 2001

Atty. Docket: 18528.127

For: **Novel Exendin Agonist Formulations
and Methods of Administration
Thereof**

Confirmation No.: 2741

TECH CENTER 1600/2900

OCT 21 2003

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


Applicants note that the article by Goke *et al.* was previously submitted with the Information Disclosure Statement filed August 20, 2002.

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.

Applicants certify that each of the documents listed on the attached Form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement and, therefore, no fee is required.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
Milan M. Vinnola (Reg. No. 45,979)

Date: October 20, 2003

ARNOLD & PORTER
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

OCT 20 2003

ATTY. DOCKET NO.

18528.127

APPLICATION NO.

09/889,330

APPLICANTS

Andrew A. YOUNG *et al.*

371 FILING DATE

December 27, 2001

ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1	6,506,724 B1	1/2003	Hiles <i>et al.</i>		
	AB1	US 2003/ 0087821 A1	5/2003	Beeley <i>et al.</i>		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AC1	AMYLIN PHARMACEUTICALS, INC., Form 10-K "Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, March 15, 2002, pages 1-8.
AD1	Baggio <i>et al.</i> , "Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice," <i>J. Biol. Chem.</i> 275(44):34471-7 (2000).
AF1	Edwards <i>et al.</i> , "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers," <i>Am. J. Physiol. Endocrinol. Metab.</i> 281:E155-61 (2001).
AG1	Egan <i>et al.</i> , "The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes," <i>J. Clin. Endocrinol. & Metab.</i> 87(3):1282-90 (2002).
AH1	Goke <i>et al.</i> , "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," <i>J. Biol. Chem.</i> 268(26):19650-55 (1993) (previously submitted on August 20, 2002).
AI1	International Search Report, International Application No. PCT/US03/16699 (August 2003)
AJ1	Tourel <i>et al.</i> , "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β -Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4," <i>Diabetes</i> 51:1443-52 (2002).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
OCT 21 2003
TECH CENTER 1600/2900